TLN-372 for advanced KRAS-mutant solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called TLN-372 for people with advanced solid tumors that have a KRAS mutation. It aims to see if the drug is safe and effective for these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor with a KRAS mutation that is advanced or has spread.
- Your cancer must be measurable on scans.
- You should be able to perform daily activities with little or no help (ECOG score 0 or 1).
- Your organs must function well enough (checked by blood tests).
- You cannot have active or past brain metastases or other central nervous system involvement.
- You cannot have had major surgery or serious injury in the last 4 weeks, or have significant heart disease, uncontrolled infections, or other conditions that raise safety risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
This trial tests a combination of two experimental drugs (SY-5933 and CT-707) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective.
This trial tests a combination of three drugs (trametinib, anlotinib, and tislelizumab) for people with KRAS-mutant non-small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
This trial tests a new drug called INCB161734 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and helps shrink tumors.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Hear when a new KRAS Mutant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.